Ubs Oconnor LLC Tarsus Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.75 - $24.62 $708,000 - $1.18 Million	-48,000 Reduced 46.48%	55,262 $982,000
Q2 2023 Aug 14, 2023	BUY	$11.57 - $19.63 $1.19 Million - $2.03 Million	103,262 New	103,262 $1.87 Billion
Q1 2023 May 15, 2023	BUY	$11.92 - $16.27 $55,726 - $76,062	4,675 Added 5.0%	98,175 $1.23 Million
Q4 2022 Feb 14, 2023	BUY	$14.12 - $18.72 $458,900 - $608,400	32,500 Added 53.28%	93,500 $0
Q3 2022 Nov 14, 2022	BUY	$14.08 - $18.5 $858,880 - $1.13 Million	61,000 New	61,000 $1.04 Billion

155

40.4M

37.9K

808K

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $884M
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.